Tirzepatide-Induced Thyroid Dysfunction After Thyroidectomy: A Case Study

Medical reports and studies are highlighting a potential association between the use of tirzepatide and the development of thyroid dysfunction. Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist used for blood sugar control and weight management, has been linked in specific cases to thyroid-related adverse effects.

A case study published in Cureus detailed thyroid dysfunction in a patient who had previously undergone a thyroidectomy and was maintaining stable levothyroxine therapy prior to the use of tirzepatide.

Case of Drug-Induced Thyroiditis

In a case report published May 31, 2025, researchers described a 32-year-old woman with no personal or family history of thyroid disease who developed painless biphasic thyroiditis after two months of tirzepatide therapy. This condition manifested as initial thyrotoxicosis followed by transient hypothyroidism.

Clinical diagnostics for the patient included:

• Negative thyroid autoantibodies.
• An ultrasound showing increased vascularity and heterogeneous echotexture, which the report noted was consistent with thyroiditis.

The medical team excluded other potential causes for the condition, including infectious, autoimmune, postpartum, and infiltrative causes, based on imaging, laboratory findings, and clinical history. Following the discontinuation of tirzepatide, the patient’s thyroid function normalized within two months without requiring additional treatment.

Research on Patients with Hypothyroidism

Beyond individual case reports, larger reviews have examined how tirzepatide affects patients with existing thyroid conditions. A study published on October 5, 2023, in the Journal of the Endocrine Society reviewed the baseline and follow-up thyroid function test results of 70 patients with hypothyroidism using the medication.

To ensure the accuracy of the data, the researchers excluded patients who met any of the following criteria:

• Insufficient data.
• Early termination of the therapy.
• Adjustments to levothyroxine doses that occurred at the same time tirzepatide was initiated.

Clinical Context and Awareness

While drug-induced thyroiditis is described as an uncommon condition, the increasing use of dual GLP-1 and GIP receptor agonists for weight and glucose management has led to greater interest in these potential side effects.

The May 31, 2025, report emphasized that these findings add to the limited existing literature and highlight the necessity for clinician awareness regarding possible thyroid-related adverse effects associated with tirzepatide.